FDA Approves Higher Strength of Novo Nordisk’s Wegovy to Compete with eli Lilly’s Zepbound
The Food and Drug Governance has given the green light to a more potent version of Novo Nordisk’s widely used weight loss injection, Wegovy. This move is part of the company’s strategy to regain its leading position in the obesity treatment market against rival Eli Lilly.
Launching the 7.2 mg Dose: A Direct Challenge to Zepbound
Novo Nordisk is set to introduce a 7.2-milligram formulation of wegovy this April, aiming squarely at competing with Eli Lilly’s obesity medication, Zepbound. Although Zepbound entered the U.S. market after Wegovy,it quickly gained popularity due to its enhanced effectiveness compared to wegovy’s original 2.4-milligram dose.
Zepbound’s superior results have made it a favored option among doctors and patients, strengthening Eli Lilly’s foothold in obesity care.
Clinical Evidence: superior Weight Loss Achieved
Data from phase three clinical trials over 72 weeks show that patients receiving high-dose wegovy lost an average of 20.7% body weight-substantially higher than the roughly 15% reduction seen with the standard dose. This advancement brings Novo Nordisk closer in performance to its competitor.
Addressing Complex Patient Needs: Obesity and Type 2 Diabetes
A separate phase three trial involving individuals managing both obesity and Type 2 diabetes demonstrated that high-dose Wegovy resulted in an average weight loss of 14.1%. Considering that people with diabetes often encounter greater difficulty losing weight than those without, these findings are especially encouraging.
“This new dosage not onyl strengthens our competitive position but also offers patients struggling on current treatments a promising path toward more significant weight loss,” stated Dr. Jason Brett, head of U.S. medical affairs at Novo Nordisk.
Fast-Tracked FDA Approval Through National Priority Voucher Program
This authorization represents a important milestone as it is the first GLP-1 receptor agonist approved under the FDA’s newly established national priority voucher program launched in mid-2025. The initiative accelerates review timelines for critical therapies addressing urgent public health challenges-from years or months down to just one or two months-speeding patient access to innovative treatments.
